Literature DB >> 21562147

Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose.

Xiuling Zhang1, Lei Li, Xinxin Ding, Laurence S Kaminsky.   

Abstract

Cytochrome P450 oxidoreductase (POR) is required for drug metabolism by all microsomal cytochrome P450 enzymes. The aim of this study was to investigate whether any of the common single nucleotide polymorphisms (SNPs) in the POR gene and its flanking intergenic sequences correlate with interindividual variations in the warfarin maintenance dose (which is determined partly by rates of warfarin metabolism) in patients undergoing anticoagulation therapy. Warfarin dose and patients' demographic and clinical information were collected from 124 patients, who had attained a stable warfarin dose while receiving treatment at the Stratton VA Medical Center. Genomic DNAs were isolated from blood samples and were genotyped for 15 SNPs (including 10 SNPs on the POR gene). Association analysis was performed on 122 male patients by linear regression. Simple regression analysis revealed that vitamin K epoxide reductase complex subunit 1 (VKORC1) -1639A>G, CYP2C9*2, CYP2C9*3, age, and chronic aspirin therapy were significantly associated with warfarin dose. In contrast, multiple regression analysis revealed that, in addition to several known factors contributing to the variations in warfarin maintenance dose (VKORC1 -1639A>G, CYP2C9*2, CYP2C9*3, CYP4F2 rs2108622, and chronic aspirin therapy), three common POR SNPs (-173C>A, -208C>T, and rs2868177) were also significantly associated with variations in warfarin maintenance dose. These results indicate, for the first time, that three common SNPs in the POR gene may contribute to the interindividual variability in warfarin maintenance dose. Further studies on functional characterization of the POR SNPs identified, including their impact on the in vivo metabolism of additional drugs, are needed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21562147      PMCID: PMC3141882          DOI: 10.1124/dmd.111.038836

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  40 in total

1.  CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.

Authors:  Paola Borgiani; Cinzia Ciccacci; Vittorio Forte; Elisabetta Sirianni; Lucia Novelli; Placido Bramanti; Giuseppe Novelli
Journal:  Pharmacogenomics       Date:  2009-02       Impact factor: 2.533

2.  An intestinal epithelium-specific cytochrome P450 (P450) reductase-knockout mouse model: direct evidence for a role of intestinal p450s in first-pass clearance of oral nifedipine.

Authors:  Qing-Yu Zhang; Cheng Fang; Jin Zhang; Deborah Dunbar; Laurence Kaminsky; Xinxin Ding
Journal:  Drug Metab Dispos       Date:  2008-12-04       Impact factor: 3.922

Review 3.  Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics.

Authors:  Hedi Schelleman; Nita A Limdi; Stephen E Kimmel
Journal:  Pharmacogenomics       Date:  2008-09       Impact factor: 2.533

4.  Nomenclature for alleles of the cytochrome P450 oxidoreductase gene.

Authors:  Sarah C Sim; Walter L Miller; Xiao-Bo Zhong; Wiebke Arlt; Tsutomu Ogata; Xinxin Ding; C Roland Wolf; Christa E Flück; Amit V Pandey; Colin J Henderson; Todd D Porter; Ann K Daly; Daniel W Nebert; Magnus Ingelman-Sundberg
Journal:  Pharmacogenet Genomics       Date:  2009-07       Impact factor: 2.089

5.  Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation.

Authors:  Ana M Gomes; Stefan Winter; Kathrin Klein; Miia Turpeinen; Elke Schaeffeler; Matthias Schwab; Ulrich M Zanger
Journal:  Pharmacogenomics       Date:  2009-04       Impact factor: 2.533

Review 6.  Genetic variation in human P450 oxidoreductase.

Authors:  Walter L Miller; Ningwu Huang; Vishal Agrawal; Kathleen M Giacomini
Journal:  Mol Cell Endocrinol       Date:  2008-09-26       Impact factor: 4.102

Review 7.  Warfarin pharmacogenetics.

Authors:  Nita A Limdi; David L Veenstra
Journal:  Pharmacotherapy       Date:  2008-09       Impact factor: 4.705

8.  CYP4F2 genetic variant alters required warfarin dose.

Authors:  Michael D Caldwell; Tarif Awad; Julie A Johnson; Brian F Gage; Mat Falkowski; Paul Gardina; Jason Hubbard; Yaron Turpaz; Taimour Y Langaee; Charles Eby; Cristi R King; Amy Brower; John R Schmelzer; Ingrid Glurich; Humberto J Vidaillet; Steven H Yale; Kai Qi Zhang; Richard L Berg; James K Burmester
Journal:  Blood       Date:  2008-02-04       Impact factor: 22.113

9.  A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.

Authors:  Fumihiko Takeuchi; Ralph McGinnis; Stephane Bourgeois; Chris Barnes; Niclas Eriksson; Nicole Soranzo; Pamela Whittaker; Venkatesh Ranganath; Vasudev Kumanduri; William McLaren; Lennart Holm; Jonatan Lindh; Anders Rane; Mia Wadelius; Panos Deloukas
Journal:  PLoS Genet       Date:  2009-03-20       Impact factor: 5.917

10.  Mapping the genetic architecture of gene expression in human liver.

Authors:  Eric E Schadt; Cliona Molony; Eugene Chudin; Ke Hao; Xia Yang; Pek Y Lum; Andrew Kasarskis; Bin Zhang; Susanna Wang; Christine Suver; Jun Zhu; Joshua Millstein; Solveig Sieberts; John Lamb; Debraj GuhaThakurta; Jonathan Derry; John D Storey; Iliana Avila-Campillo; Mark J Kruger; Jason M Johnson; Carol A Rohl; Atila van Nas; Margarete Mehrabian; Thomas A Drake; Aldons J Lusis; Ryan C Smith; F Peter Guengerich; Stephen C Strom; Erin Schuetz; Thomas H Rushmore; Roger Ulrich
Journal:  PLoS Biol       Date:  2008-05-06       Impact factor: 8.029

View more
  22 in total

1.  The P450 oxidoreductase (POR) rs2868177 and cytochrome P450 (CYP) 2B6*6 polymorphisms contribute to the interindividual variability in human CYP2B6 activity.

Authors:  Li-Chen Gao; Fang-Qun Liu; Li Yang; Lin Cheng; Hai-Ying Dai; Ran Tao; Shi-Peng Cao; Di Wang; Jie Tang
Journal:  Eur J Clin Pharmacol       Date:  2016-07-20       Impact factor: 2.953

2.  The prevalence of VKORC1 1639 G>A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population.

Authors:  Coskun Silan; Omer Tamer Dogan; Fatma Silan; Fatma Mutlu Kukulguven; Halil Fatih Asgun; Semra Ozdemir; Ahmet Uludag; Sinem Atik; Buket Gungor; Seçil Akdur; Hakki Engin Aksulu; Oztürk Ozdemir
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

3.  Weight of ABCB1 and POR genes on oral tacrolimus exposure in CYP3A5 nonexpressor pediatric patients with stable kidney transplant.

Authors:  G N Almeida-Paulo; I Dapía García; R Lubomirov; A M Borobia; N L Alonso-Sánchez; L Espinosa; A J Carcas-Sansuán
Journal:  Pharmacogenomics J       Date:  2017-01-17       Impact factor: 3.550

4.  Proximal Tubular Vacuolization and Hypersensitivity to Drug-Induced Nephrotoxicity in Male Mice With Decreased Expression of the NADPH-Cytochrome P450 Reductase.

Authors:  Liang Ding; Lei Li; Senyan Liu; Xiaochen Bao; Kathleen G Dickman; Stewart S Sell; Changlin Mei; Qing-Yu Zhang; Jun Gu; Xinxin Ding
Journal:  Toxicol Sci       Date:  2020-02-01       Impact factor: 4.849

5.  Influence of genetic polymorphisms in cytochrome P450 oxidoreductase on the variability in stable warfarin maintenance dose in Han Chinese.

Authors:  Wu-Tao Zeng; Qing Xu; Cheng-Hsun Li; Wei-Yan Chen; Xiu-Ting Sun; Xiang Wang; Yi-Ying Yang; Hui Shi; Zhi-Sheng Yang
Journal:  Eur J Clin Pharmacol       Date:  2016-08-04       Impact factor: 2.953

6.  The POR rs1057868-rs2868177 GC-GT diplotype is associated with high tacrolimus concentrations in early post-renal transplant recipients.

Authors:  Shu Liu; Rong-Xin Chen; Jun Li; Yu Zhang; Xue-Ding Wang; Qian Fu; Ling-Yan Chen; Xiao-Man Liu; Hong-Bing Huang; Min Huang; Chang-Xi Wang; Jia-Li Li
Journal:  Acta Pharmacol Sin       Date:  2016-08-08       Impact factor: 6.150

7.  Structural basis for human NADPH-cytochrome P450 oxidoreductase deficiency.

Authors:  Chuanwu Xia; Satya P Panda; Christopher C Marohnic; Pavel Martásek; Bettie Sue Masters; Jung-Ja P Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-01       Impact factor: 11.205

8.  Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients.

Authors:  Ling Xue; Nick Holford; Xiao-Liang Ding; Zhen-Ya Shen; Chen-Rong Huang; Hua Zhang; Jing-Jing Zhang; Zhe-Ning Guo; Cheng Xie; Ling Zhou; Zhi-Yao Chen; Lin-Sheng Liu; Li-Yan Miao
Journal:  Br J Clin Pharmacol       Date:  2016-11-25       Impact factor: 4.335

9.  Genetic variations in NADPH-CYP450 oxidoreductase in a Czech Slavic cohort.

Authors:  Mária Tomková; Satya Prakash Panda; Ondřej Šeda; Alice Baxová; Martina Hůlková; Bettie Sue Siler Masters; Pavel Martásek
Journal:  Pharmacogenomics       Date:  2015       Impact factor: 2.533

10.  Associations of cytochrome P450 oxidoreductase genetic polymorphisms with smoking cessation in a Chinese population.

Authors:  Huijie Li; Suyun Li; Qiang Wang; Chongqi Jia
Journal:  Hum Genet       Date:  2016-09-22       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.